** GENERIC SPECIALS - DEEP DISCOUNTS **

"Generics Campaign"

UPDATED CAMPAIGN DATES 3/4/22 - 3/31/22

Regular ordering through McKesson - discount PERCENTAGE
will be in place during campaign period.

Prices are effective as of 3/4/22 and are subject to change with or without notice.
Please note – changes are marked in YELLOW.

NOTE: APCI Invoice price represents gross invoice price not net of rebates and dividends. To download this table as an Excel spreadsheet that includes items by classification AND alphabetically, click here.

Custom Price List Frequently Asked Questions

Have you heard about the Markdown Meds Monthly program?

Once a month you can automatically receive an order from Masters Drug Company that is based on your current dispense / purchase history.

These items will have at least a 20% guaranteed savings below APCI program prices.

These items are sold at net price, without rebates and are non-returnable. These items will count towards your APCI / McKesson program compliance metrics.

Ask your APCI sales rep for more details. 

Why is the A Slot item not substituting?

One reason the A Slot item may not be substituting is because the B slot is also out of stock.  There is No substitution to AC slots.  AC slots are NOT a part of substitution.  If a customer wants to receive an AC slot, they will have to place an order for it.  Nothing subs to or away from an AC slot.

Are the Purchases for non APC1 items counting toward my compliance?

Yes, as long as you are still purchasing another item from McKesson in Connect it is contributing toward the 90/90 compliance, but does not count toward your OneStop generics total, so you receive less of a rebate on the non APC1 items.

Why are so many CPL items on allocation?

In most cases the items are not on allocation except at the store level. The CPL and OneQ suggest purchasing opportunities based on 90-day history. McKesson uses the same method, meaning you may have ordered 8 in the past 90 days and after your 90-day allocation of 8 you may only receive 1 at a time per day. If you do not want to repeat the order to buy forward day after day the procedure is to inform the McKesson Rep of an amount you would like in one order and let them remove the store level allocation on the item.

I prefer the alphabetical Dispatch how do I print that view?

The listing directions are just above the Classifications view. When you click to download this table as an Excel spreadsheet it will default to the alphabetical view page first and includes items by classification on second tab each for print options.

Thank you for sharing your questions and tips. If you would like to submit a question or a tip, please send to charlotteg@apcinet.com

FORMULARY CHANGES:

We have received request from many of you asking how to determine when changes to the formulary items on our One Stop program will occur. There is a list available on the OneStop Generics homepage. Click here to go to the homepage and select the list to review under the Formulary Changes banner.

REASONS FOR CHANGES TO FORMULARY:

• Formulation Change: A manufacturer may change product formulation, for example, in response to user preference.
• Supply Discontinuation: A manufacturer may discontinue supplying a product.
• Supply Issues: A manufacturer change may be initiated to insure more reliable supply and higher customer service levels
• Price: If market prices begin to change McKesson Sourcing Team will seek other suppliers to provide better pricing to our members.

APCI 2022-23 Flu Vaccine Program Update

Listed below is the current status of APCI’s flu vaccine program for 2022-23. Please remember that all flu vaccine pre-orders need to be placed before April 15, 2022. Please see the following page for pricing and manufacturer information. For questions, please contact APCI Clinical Affairs.

Click the image below to open a printable PDF file with information about Seqirus' flu vaccine information and ordering for the 2022-2023 flu season.

Medicare update for VAXNEUVANCE^™
(Pneumococcal 15-valent Conjugate Vaccine)

Effective December 10, 2021, Medicare announced coverage for VAXNEUVANCE and will be backdated to July 2021.

Indications and Usage

VAXNEUVANCE is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older.

Select Safety Information

Do not administer VAXNEUVANCE to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid. 

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE. 

Select Safety Information continues below.

Click below for more information.

Select Safety Information (continued)

The most commonly reported solicited adverse reactions in individuals 18 through 49 years of age were: injection-site pain (75.8%), fatigue (34.3%), myalgia (28.8%), headache (26.5%), injection-site swelling (21.7%), injection-site erythema (15.1%), and arthralgia (12.7%). 

The most commonly reported solicited adverse reactions in individuals 50 years of age and older were: injection-site pain (66.8%), myalgia (26.9%), fatigue (21.5%), headache (18.9%), injection-site swelling (15.4%), injection-site erythema (10.9%), and arthralgia (7.7%). 

Vaccination with VAXNEUVANCE may not protect all vaccine recipients. 

Before administering VAXNEUVANCE, please read the accompanying Prescribing Information. The Patient Information also is available.